Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Luo, Lei ^a   Sun, Zhaolin ^a   Wu, Weidong ^a   Luo, Guangheng ^a  

^a Guizhou Province People's Hospital   (China)

Author keywords

Chronic allograft nephropathy; Kidney transplantation; Mycophenolate Mofetil; Renal fibrosis; Tacrolimus

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOWN REGULATION; HISTOPATHOLOGY; KIDNEY FIBROSIS; MALE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; STAINING; UPREGULATION;

ANIMALS; CHRONIC DISEASE; DRUG INTERACTIONS; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RATS; RATS, INBRED F344; RATS, INBRED LEW; TACROLIMUS; TREATMENT OUTCOME;

EID: 84863109009     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-53     Document Type: Article

References (27)

1. Chronic renal allograft dysfunction. Chapman JR, OConnell PJ, Nankivell BJ, J Am SocNephrol 2005 16 3015 26
2. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Joosten SA, van Kooten C, Sijpkens YW, deFijter JW, Paul LC, Kidney Int 2004 65 1556 9 10.1111/j.1523-1755.2004.05410.x 15086891
3. The Banff 97 working classification of renal allograft pathology. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. Kidney Int 1999 55 713 23 10.1046/j.1523-1755.1999.00299.x 9987096
4. The natural history of chronic allograft nephropathy. Nankivell BJ, Borrows RJ, Fung CL, OConnell PJ, Allen RD, Chapman JR, N Engl J Med 2003 349 2326 33 10.1056/NEJMoa020009 14668458
5. Chronic allograft nephropathy - a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. Campistol JM, Boletis IN, Dantal J, de Fijter JW, Hertig A, Neumayer HH, et al. Clin Transplant 2009 23 769 777 10.1111/j.1399-0012.2009.01057.x 19719730
6. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Shihab FS, Bennett WM, Tanner AM, Andoh TF, Transplantation 1997 64 12 1829 10.1097/00007890-199712270-00034 9422427
7. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK 506: Clinical significance and comparison with cyclosporine. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ, Am J SurgPathol 1993 17 1 60
8. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor free regimens in cadaveric renal transplantation. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, et al. Transplantation 2004 77 8 1228 1235 10.1097/01.TP.0000121504.69676.5E 15114090
9. Mycophenolate Mofetil but Not the Type of Calcineurin Inhibitor (Cyclosporine vsTacrolimus) Influences the Intragraft mRNA Expression of Cytokines in Human Kidney Allograft Biopsies byIn Situ RT-PCR Analysis. Kaminska D, Tyran B, Mazanowska O, Letachowicz W, Kochman A, Rabczynski J, et al. Transplant Proc 2005 37 2 770 772 10.1016/j.transproceed.2004.12.144 15848526
10. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways. Gao R, Lu Y, Xin YP, Zhang XH, Wang J, Li YP, Transplant Proc 2006 38 7 2154 2157 10.1016/j.transproceed.2006.06.006 16980029
11. Conversion From Cyclosporine to Mycophenolate Mofetil Improves Expression of A20 in the Rat Kidney Allografts Undergoing Chronic Rejection. Teng D, Lu YP, Gao R, Xin Y, Cao G, Li X, et al. Transplant Proc 2006 38 7 2164 2167 10.1016/j.transproceed.2006.06.007 16980032
12. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Leask A, Keio J Med 2004 53 2 74 7 10.2302/kjm.53.74 15247510
13. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, et al. Am J Transplant 2006 6 10 2292 2306 10.1111/j.1600-6143.2006.01493.x 16889607
14. A new rat model of transplant arteriosclerosis accelerated by I/R injury. Lu YP, Chen WG, Wang I, Li YP, Transplant Proc 2003 35 184 10.1016/S0041- 1345(02)03942-8 12591358
15. Inhibition of connection tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Luo GH, Lu YP, Song J, Yang L, Shi YJ, Li YP, Transplantation Proc 2008 40 2365 2369 10.1016/j.transproceed.2008.07.100
16. Newer immunosuppressive drugs: A review. Gummert JF, Ikonen T, Morris RE, J Am SocNephrol 1999 10 1366 1380
17. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Jackson RC, Weber G, Morris HP, Nature 1975 256 331 3 10.1038/256331a0 167289
18. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Sintchak MD, Nimmesgern E, Immunopharmacology 2000 47 163 84 10.1016/S0162-3109(00)00193-4 10878288
19. Mycophenolatemofetil and its mechanisms of action. Allison AC, Eugui EM, Immunopharmacology 2000 47 85 118 10.1016/S0162-3109(00)00188-0 10878285
20. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Eugui EM, Almquist SJ, Muller CD, Allison AC, Scand J Immunol 1991 33 161 73 10.1111/j.1365-3083.1991.tb03746.x 1826793
21. The role of epithelial-to-mesenchymal transition in renal fibrosis. Zeisberg M, Kalluri R, J Mol Med 2004 82 3 175 81 10.1007/s00109-003-0517-9 14752606
22. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, et al. J BiolChem 2003 278 14 12384 9
23. Interstitial expression of alpha-SMA: an early marker of chronic renal allograft dysfunction. Badid C, Desmouliere A, Babici D, Hadj-Aissa A, McGregor B, Lefrancois N, et al. Nephrol Dial Transplant 2002 17 11 1993 8 10.1093/ndt/17.11.1993 12401859
24. Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Medici D, Hay ED, Goodenough DA, MolBiol Cell 2006 17 4 1871 9
25. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF, Am J Transplant 2005 5 6 1367 74 10.1111/j.1600-6143.2005.00843.x 15888043
26. Collagen I upregulates extracellular matrix gene expression and secretion of TGF-beta 1 by cultured human mesangial cells. Ortega-Velazquez R, Gonzalez-Rubio M, Ruiz-Torres MP, Diez-Margues ML, Lglesias MC, Rodriguez-Puyol M, et al. Am J Cell Physiol 2004 286 6 1335 43 10.1152/ajpcell.00279.2003
27. Secretion of collagen type IV by human renal fibroblasts is increased by high glucose via a TGF-beta- independent pathway. Lam S, van der Geest RN, Verhagen NA, Daha MR, van Kooten C, Nephrol Dial Transplant 2004 19 7 1694 701 10.1093/ndt/gfh235 15150349